Cellebrite wird am 13. August 2026 die Finanzergebnisse für das zweite Quartal 2026 bekannt geben
/PRNewswire/ -- Cellebrite DI Ltd. (NASDAQ: CLBT), ein weltweit führender Anbieter von KI-gestützten Lösungen für digitale Ermittlungen und
CLBT - Cellebrite DI Ltd.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$19.75
DETAILS
HIGH:
$23.00
LOW:
$15.00
MEDIAN:
$20.50
CONSENSUS:
$19.75
UPSIDE:
38.94%
Stock News
Cellebrite to Report Second-Quarter 2026 Financial Results on August 13, 2026
TYSONS CORNER, Va. and PETAH TIKVA, Israel, July 21, 2026 /PRNewswire/ -- Cellebrite DI Ltd.
Cellebrite CEO Thomas Hogan Sells 103,000 Shares for $1.6 Million: Is This a Concern for Investors?
Hogan's non-discretionary sale satisfied tax withholding obligations from vesting RSUs. He retains 590,777 shares worth $9.25 million.
Cellebrite Expands Exclusive SkySafe Partnership to Deliver Immediate Drone Detection and Airspace Intelligence for Digital Investigations at Scale
The partnership unifies what happens in the sky with what's stored on the drone in a single investigative workflow TYSONS CORNER, Va. and PETAH TIKVA, Israel, July 8, 2026 /PRNewswire/ -- Cellebrite DI Ltd.
Cellebrite: Stronger Fundamentals Support A Buy Rating
Cellebrite (CLBT) remains a buy as fundamentals strengthen, with FedRAMP High achieved and federal demand reaccelerating. Q2 ARR guidance of $510–513M implies 22–23% growth, supporting a narrative of renewed momentum post-federal softness. Platform adoption advances, with Inseyets conversions near 60% and growth products now 14% of ARR, lengthening CLBT's growth runway.
Cellebrite DI Ltd. (CLBT) Discusses AI Technology and Innovation in Tech Talk Transcript
Cellebrite DI Ltd. (CLBT) Discusses AI Technology and Innovation in Tech Talk Transcript
Cellebrite Launches the New Age of Investigations with Genesis, Now Generally Available
Reduces investigative workloads from weeks to minutes accelerating investigations like never before TYSONS CORNER, Va. and PETAH TIKVA, Israel, June 10, 2026 /PRNewswire/ -- Cellebrite DI Ltd.
Cellebrite kündigt bevorstehende Investorenveranstaltungen am 10. Juni 2026 an
/PRNewswire/ -- Cellebrite DI Ltd. (NASDAQ: CLBT), ein weltweit führender Anbieter von KI-gestützten Lösungen für digitale Ermittlungen und
Cellebrite Announces Upcoming Investor Events on June 10, 2026
Cellebrite Announces Upcoming Investor Events on June 10, 2026 PR Newswire TYSONS CORNER, Va. and PETAH TIKVA, I
3 Growth Stocks Worth $5,000 of Your Money -- Even in This Market
Credo, Cellebrite, and TransMedics are building dominant positions in huge markets with years of expansion still ahead.
Cellebrite Announces Upcoming Investor Events on June 10, 2026
TYSONS CORNER, Va. and PETAH TIKVA, Israel, June 5, 2026 /PRNewswire/ -- Cellebrite DI Ltd.
Cellebrite DI Eyes AI, Cloud and FedRAMP as Digital Investigations Demand Grows
Cellebrite DI NASDAQ: CLBT executives said the company is seeing broader customer adoption of its digital investigations platform, with artificial intelligence, cloud migration and U.S. federal authorization expected to shape its next phase of growth.
CGNT vs. CLBT: Which Intelligence Software Stock Offers Better Upside?
Cognyte and Cellebrite are riding AI-driven investigative demand - dig into their growth, profitability, valuation and risks to see which offers better upside.
Cellebrite DI Sees Federal Rebound as AI, Defense Tools Fuel New Growth
Cellebrite DI NASDAQ: CLBT executives said the digital investigations company is seeing renewed momentum in government demand, international markets and new product categories, including artificial intelligence and defense-focused capabilities, during a JPMorgan cybersecurity and DevOps event hosted by analyst Brian Essex.
Cellebrite DI Ltd. (CLBT) Presents at J.P.
Cellebrite DI Ltd. (CLBT) Presents at J.P.
Cellebrite: Positive Q1 Results, But There Is Room For Margin Improvements
Cellebrite delivered strong Q1 2026 results, with 19% revenue growth and notable subscription and ARR gains, beating analyst expectations. CLBT expanded its portfolio with the SCG Canada acquisition and launched AI-powered solutions, positioning itself for long-term growth and broader market reach. Despite robust top-line growth, gross, operating, and net margins declined; margin expansion remains a key area to monitor.
Cellebrite DI Ltd. (CLBT) Q1 2026 Earnings Call Transcript
Cellebrite DI Ltd. (CLBT) Q1 2026 Earnings Call Transcript
Cellebrite DI Q1 Earnings Call Highlights
Cellebrite DI NASDAQ: CLBT reported first-quarter 2026 results that management said met or exceeded the high end of its guidance for annual recurring revenue and adjusted EBITDA, while executives highlighted a wave of new product launches centered on artificial intelligence, cloud-based case management and mobile device access.
Cellebrite DI Ltd. (CLBT) Q1 Earnings and Revenues Top Estimates
Cellebrite DI Ltd. (CLBT) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.11 per share.
Cellebrite Announces First-Quarter 2026 Results
First-Quarter ARR Growth of 21% and TTM Free Cash Flow Margin of 32% Q2 Outlook Highlights ARR Acceleration TYSONS CORNER, Va. and PETAH TIKVA, Israel, May 14, 2026 /PRNewswire/ -- Cellebrite DI Ltd.
Price Targets
Cellebrite initiated with a Buy at DA Davidson
$20.00
(was $12.89)
D.A. Davidson
Cellebrite price target lowered to $15 from $18 at Needham
$15.00
(was $13.03)
Needham
Cellebrite price target lowered to $21 from $23 at Lake Street
$21.00
(was $13.86)
Eric Martinuzzi
·
Lake Street
Cellebrite price target lowered to $23 from $25 at TD Cowen
$23.00
(was $13.85)
UBS
Cellebrite price target lowered to $18 from $24 at Needham
$18.00
(was $14.26)
Needham
Cellebrite price target raised to $20 from $17 at BofA
$20.00
(was $18.11)
Tomer Zilberman
·
Bank of America Securities
Cellebrite price target raised to $23 from $20 at Craig-Hallum
$23.00
(was $16.86)
Jeff Van Rhee
·
Craig-Hallum
Cellebrite (CLBT) PT Raised to $17 at Lake Street Capital Markets
$17.00
(was $16.14)
Eric Martinuzzi
·
Loop Capital Markets
Cellebrite price target raised to $17 from $13 at BofA
$17.00
(was $14.96)
Tomer Zilberman
·
Bank of America Securities
Cellebrite price target raised to $16 from $14 at Craig-Hallum
$16.00
(was $11.08)
Jeff Van Rhee
·
Craig-Hallum